LEO Pharma Nears EU Approval for Anzupgo® in Adolescents With Chronic Hand Eczema — LEO Pharma A/S

Event summary

CHMP recommends label expansion for Anzupgo® (delgocitinib) cream to include adolescents aged 12–17 with moderate to severe chronic hand eczema in the EU.
Positive opinion based on DELTA TEEN trial, which met primary and key secondary endpoints.
Anzupgo® is already approved for adults in the EU and several other markets, including the U.S.
Chronic hand eczema affects approximately 4.7% of the global population, with significant psychosocial and functional burdens.

The big picture

LEO Pharma's positive CHMP opinion for Anzupgo® in adolescents underscores the growing focus on pediatric dermatology, an underserved segment with significant unmet needs. The approval, if finalized, would expand LEO Pharma's market reach in chronic hand eczema, a condition affecting millions globally. This move aligns with broader industry trends toward developing targeted treatments for chronic skin conditions, particularly in younger populations.

What we're watching

Regulatory Timing: The pace at which the European Commission finalizes approval for Anzupgo® in adolescents, typically within a few months of a positive CHMP opinion.
Market Expansion: Whether LEO Pharma can leverage this approval to expand Anzupgo®'s reach in other pediatric dermatology indications.
Competitive Dynamics: How this move positions LEO Pharma against competitors in the chronic hand eczema space, particularly in the adolescent demographic.